CW January 2003
Volume 12Issue Number 1 January 2003 ISSN 10593802 New Treatment for Invasive Refractory AspergillosisMicafungin, a glucan synthesis-inhibitor of the echinocandin structural class, may have potent therapeutic effects for fighting refractory invasive aspergillosis in bone marrow transplant (BMT) patients. Glucan is an essential component of the fungal cell wall. Allogeneic BMT patients with aspergillosis have a poor prognosis, with published success rates for conventional therapy in the 13%-19% range. Standard treatment has been with amphotericin B.
Go to Previous Page Go to Next Page Source & Addtional Reading V. Ratanatharathorn, 44th Annual Meeting of the American Society of Hematology. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW January 2003Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
